Vaccines & Immunotherapies
Online Symposium
26 September 2024 | Online, BST (UTC+1)
Bringing together key opinion leaders from across the globe for focused discussions on modern vaccine technologies & development
Sponsored By
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.
SGS is the world’s leading inspection, verification, testing and certification company. With more than 90,000 employees, SGS operates a network of over 1,500 offices and laboratories around the world.
The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS Vitrology provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses, and other potential contaminants. SGS Vitrology helps clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified, and US FDA audited.
The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS Vitrology provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses, and other potential contaminants. SGS Vitrology helps clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified, and US FDA audited.
Key Topics Covered
- Modern vaccine technologies:
» mRNA - Advances in vaccine delivery systems and routes of administration:
» LNP delivery - Addressing vaccine stability and cold chain reduction strategies
- Case studies in vaccine development for cancer and infectious diseases
Benefits of Attending
- Meet with global key innovators in a focused symposium to hear the latest case studies in vaccines & immunotherapies. This programme takes a deep dive into best practice vaccine development approaches & technological advancements, bringing together thought leaders from across the globe for focused discussions & networking
- Take a deep dive into immunotherapy strategies for cancer and autoimmune diseases. Delve into the latest innovations in cancer immunotherapy, including the discovery of new targets, as well as immunomodulatory vaccines for autoimmune disease care
- Gain a comprehensive understanding of vaccine delivery systems & adjuvant production. From advances in vaccine administration through to modes of action and regulatory considerations
- Followed by the release of the ‘Harnessing Vaccine Technologies & Immunotherapies with Best Practice Approaches’ report detailing key insights, methodologies, and emerging trends discussed during the event for leveraging vaccines and immunotherapies effectively
Latest Resources
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Meet Our Expert Speakers
Vaccines & Immunotherapies Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Confirmed speakers include:
Amita Vaidya
Principal Scientist,
Sanofi
Brian Schanen
Global Head,
Sanofi
Eric Halioua
Chief Executive Officer,
PDC* Line Pharma
Mabrouka Maamra
Project Manager,
University of Sheffield
Mats Lundgren
CSO,
Abera Bioscience
Ola Nilsson
Head of Neoantigen Production & Development,
NEOGAP Therapeutics AB
Samantha Paston
Head of translational research,
Scancell ltd
Tobias von der Haar
Professor of Systems Biology,
University of Kent
Register Your Interest
Submit your details and a member of our team will be in touch